ライフサイエンスコーパス: NaI

1 NF-kappaB or NF-kappaB activation inhibitor (NAI).

2 ucleotide Analogue Interference Suppression (NAIS).

3 resistant to neuraminidase (NA) inhibitors (NAIs).

4 susceptibility to neuraminidase inhibitors (NAIs).

5 y prior depletion of intracellular free Na+ (Nai+).

6 malaria model incorporating vaccination and NAI.

7 oid carcinoma after administration of (124)I-NaI.

8 lling of the clonal landscape in response to NAI.

9 inhibited by the presence of the respective NAI.

10 ing influenza A viruses in susceptibility to NAIs.

11 influenza viruses tested were susceptible to NAIs.

12 our study may help to optimize the design of NAIs.

13 ve not been reported to confer resistance to NAIs.

14 spective purified substrates, we showed that NAI-107 forms complexes with bactoprenol-pyrophosphate-c

15 The lantibiotic NAI-107 is active against Gram-positive bacteria includi

16 w membrane depolarization was observed after NAI-107 treatment, which could contribute to killing of

17 and stress), 123I-/124I-/131I-OIH, 123I/131I-NaI, 125I-iothalamate, 111In-DTPA and 89Sr-SrCl.

18 total of 212 children were studied: 46 with NAIS, 34 with APPIS, 55 with PVI, and 77 controls (male,

19 inhibitory concentrations against all tested NAIs (827-, 25-, 286-, and 702-fold for zanamivir, oselt

20 ntitatively profiled by ESI-MS analysis with NaI additive.

21 on of iodine species such as HIO and I2 from NaI aerosolized solutions exposed to 50 ppbv O3 can occu

22 so rapidly determining the effectiveness of NAIs against new viral strains is vital for deciding how

23 associated with contact ion-pair binding of NaI (alpha = 1300, DeltaGalpha = -18 kJ mol(-1)) and NaC

24 of (125)I-DCIBzL, 111 MBq (3 mCi) of (125)I-NaI, an equivalent amount of nonradiolabeled DCIBzL, or

25 ene expression patterns intermediate between NAI and EFFE T cells.

26 The addition of NaI and NaSCN altered the properties of visco-elastic ma

27 ) exhibited reduced inhibition by all of the NAIs and two variants (E119D and E119D-H274Y) retained t

28 za antivirals, the neuraminidase inhibitors (NAIs) and the adamantanes, are well characterized, as ar

29 However, neuraminidase-inhibiting (NAi) antibodies can reduce viral spread and may be of pa

30 Analyses suggested an independent role for NAI antibody in protection, which was similar in the IIV

31 While NAI antibody is not produced to a large extent in respon

32 re we demonstrate the effective induction of NAi antibody titers after H5N1 vaccination in humans.

33 Neuraminidase inhibitor (NAI) antiviral drugs can shorten the duration of uncompl

34 The conserved residues that interact with NAIs are under selective pressure, but only a few have b

35 Neuraminidase inhibitors (NAIs) are antivirals designed to target conserved residu

36 Neuraminidase inhibitors (NAIs) are stockpiled internationally for extended use in

37 Currently, neuraminidase (NA) inhibitors (NAIs) are the first choice for influenza prevention and

38 The neuraminidase (NA) inhibitors (NAIs) are the frontline anti-influenza drugs and are the

39 Although neuraminidase (NA) inhibitors (NAIs) are the only class of antiviral drugs available fo

40 Neuraminidase (NA) inhibitors (NAIs) are the only class of drugs available to treat inf

41 Neuraminidase (NA) inhibitors (NAIs) are the primary option for treatment, but informat

42 lassified neonatal arterial ischemic stroke (NAIS), arterial presumed perinatal ischemic stroke (APPI

43 positive detection mode using sodium iodide (NaI) as an additive.

44 olyzes ATP to export three intracellular Na (Nai) as it imports two extracellular K (Ko) across anima

45 ility of vaccines, neuraminidase inhibitors (NAIs), as the only available class of drugs for AIVs in

46 The NAI assay detected a vaccine response in 37% of IIV reci

47 MN assay titers were highly correlated, but NAI assay titers exhibited less of a correlation.

48 In IIV recipients, as NAI assay titers rose, the frequency of infection fell,

49 dized lectin-based neuraminidase inhibition (NAI) assay.

50 6, and D151) that directly interact with the NAIs but have not been reported to confer resistance to

51 a signal from the intracellular compartment (Nai) compared with an external standard (monitored by Na

52 owever, analysis of this model revealed that NAI, compounded by a subpopulation with only partial pro

53 using pairs of spherical ions (NaCl > NaBr > NaI) correlates to experimental observations (NaI > NaCl

54 were examined in the presence of 3 and 25 mM NaI, corresponding to I(-)-activated and I(-)-inhibited

55 r certain substrates without the addition of NaI, could be used in loadings of < or =1 mol %.

56 ead gamma camera equipped with 2.54-cm-thick NaI crystals operating in coincidence mode.

57 Chemoprophylaxis with NAIs decreased the frequency of symptomatic influenza (r

58 Activity was monitored by using an NaI detector.

59 ion to explore the possibility of extracting NAI drug efficacy using only the observed viral titer de

60 We isolated NAI, EFFE, and MEM CD8(+) T cell subsets from human peri

61 tified 156 genes that strongly differentiate NAI, EFFE, and MEM CD8(+) T cells; these genes provide p

62 ed ex vivo from cervical lymph node cells of NaI-fed or control mice, suggesting that the iodide-rich

63 in intensive care units (ICUs) treated with NAIs for influenza A(H1N1)pdm09 (pH1N1).

64 ifluorocarbene (generated from PhHgCF(3) and NaI) gave diastereomeric mixtures of the 2,2-difluorospi

65 difluorocarbene [generated from (CF3)2Hg and NaI] gave a diastereomeric mixture of the 3',4'-difluoro

66 aI) correlates to experimental observations (NaI > NaClO4).

67 ced in the following order: NaSCN > NaClO4 > NaI > NaNO3 approximately NaBr > NaCl > pure water appro

68 NAI had no effect.

69 For LAIV recipients, the NAI, HAI, and MN assays detected responses in 6%, 21%, a

70 Neuraminidase inhibitors (NAIs) have been widely used to control influenza virus i

71 e less effort in vaccination as the level of NAI in a population, and as disease prevalence, increase

72 rin pairs per volume of MOF that bind PC and NAI in such a way that they are primed to form the requi

73 bulin autoantibodies when they receive 0.05% NaI in their drinking water beginning at 8 wk of age.

74 NOD.H-2h4 mice given NaI in their drinking water develop iodine-accelerated s

75 utoimmune thyroiditis (SAT) when given 0.05% NaI in their drinking water, whereas B cell-deficient NO

76 IFN-gamma(-/-)NOD.H-2h4 mice given 0.05% NaI in their water develop severe thyroid epithelial cel

77 e effectiveness of neuraminidase inhibitors (NAIs) in humans infected with influenza A(H7N9) viruses

78 e effectiveness of neuraminidase inhibitors (NAIs) in reducing mortality when given to hospitalized p

79 ically relevant nicotine aerosol inhalation (NAI) induced transient reduction and irregular fluctuati

80 rehensive understanding of the mechanisms of NAI-induced inhibition of influenza virus and help lead

81 ates uterine blood vessels, counteracted the NAI-induced reduction in uterine blood flow.

82 y acquired immunity (NAI) to severe malaria; NAI is caused by repeated exposure to infectious bites a

83 Because NAI is derived from mechanistic models, it is both easie

84 he HDH reactivity of HACs in the presence of NaI is rather low.

85 ) mice develop severe TEC H/P, and 2-3 wk of NaI is sufficient for optimal development of severe TEC

86 tivirals, the neuraminidase (NA) inhibitors (NAIs), is a public health concern.

87 ation is eliminated using the sodium iodide (NaI) isolation method and that the level of oxo8dG in nu

88 cation of the recently introduced chaotropic NaI method, reducing our estimate of the level of steady

89 ance and continued surveillance of potential NAI multidrug-resistant influenza virus variants, as wel

90 cells are treated with the icSHAPE chemical NAI-N3 followed by selective chemical enrichment of NAI-

91 followed by selective chemical enrichment of NAI-N3-modified RNA, which provides an improved signal-t

92 define the nonsense error adaptation index (NAI) of the allele or a contiguous subset thereof.

93 The effect of changes of Nai+ on Nao+-sensitive transient current was investigate

94 The effects of lowering Nai+ on pre-steady-state transient current can be accoun

95 e extracted from the Paracoccus membranes by NaI or alkaline treatment, unlike the peripheral subunit

96 e extracted from the Paracoccus membranes by NaI or alkaline treatment, which is consistent with the

97 terface when increasing the concentration of NaI or NaBr from 0.010 to 100 muM.

98 Treatments with chaotropic reagents (urea, NaI, or NaBr) or with alkaline buffer (pH 10-12) resulte

99 The NAI oseltamivir (5, 20, or 80 mg/kg/day) was administere

100 utation (H274Y) conferring resistance to the NAI oseltamivir emerged worldwide in the A/H1N1 virus su

101 ed resistant variants in the presence of the NAIs oseltamivir carboxylate and zanamivir in MDCK cells

102 ltidrug resistance to the currently approved NAIs oseltamivir, zanamivir, and peramivir by assessing

103 in N6, and 4 in N8) conferred resistance to NAIs (oseltamivir carboxylate, zanamivir, or peramivir)

104 utions associated with reduced inhibition by NAIs (oseltamivir, zanamivir, and peramivir): (i) novel

105 al planar gamma-camera images and whole-body NaI probe counts were obtained to estimate (131)I-antibo

106 aotropic technique of DNA isolation by using NaI produced the lowest and least variable oxo8dG values

107 lving Rh-catalyzed aziridination followed by NaI-promoted rearrangement to an isomeric cyclic sulfami

108 I compare to different alkali metal iodides: NaI, RbI, CsI; also investigation of different potassium

109 rse effects were not increased overall among NAI recipients (RR, 1.01 [CI, 0.94 to 1.08]; RD, 0.1 per

110 ention for AIV-infected patients, studies on NAI resistance among AIVs have been limited, and markers

111 NA amino acid substitutions associated with NAI resistance among influenza viruses of N3, N7, and N9

112 sential to identify the molecular markers of NAI resistance among specific NA subtypes of avian influ

113 by a S31N mutation in the matrix gene, while NAI resistance can result from a number of mutations in

114 Although various mutations associated with NAI resistance have been identified, the amino acid subs

115 To screen for substitutions conferring NAI resistance in AIVs of N4, N5, N6, and N8 NA subtypes

116 ort profiles of NA substitutions that confer NAI resistance in AIVs of the N4, N5, N6, and N8 NA subt

117 ating antiviral susceptibility monitoring of NAI resistance in AIVs.IMPORTANCE The frequency of human

118 he molecular changes in NA that could confer NAI resistance in avian viruses grown in immortalized mo

119 gence of a single NA mutation conferring pan-NAI resistance in the clinical setting reinforces the pr

120 We identified 16 NA substitutions conferring NAI resistance in the tested AIV subtypes; some are nove

121 strate that each NA subtype possesses unique NAI resistance markers, and knowledge of these substitut

122 For NAI resistance mutation detection, we used a mutation-sp

123 Previously, we identified unique NAI resistance substitutions in AIVs of the N3, N7, and

124 Substitutions conferring NAI resistance were mainly categorized as either novel N

125 (RT-qPCR) for influenza type and subtype and NAI resistance.

126 ed, sequenced, and phenotypically tested for NAI resistance.

127 everse genetics (rg) that is associated with NAI resistance.

128 ed in 2008 to study neuraminidase inhibitor (NAI) resistance and clinical outcome.

129 Since most studies have focused on NAI-resistance in human influenza viruses, we investigat

130 The fitness of NAI-resistant influenza B viruses has not been widely st

131 o use NHBE cells to determine the fitness of NAI-resistant influenza B viruses.

132 ne the replicative capacities and fitness of NAI-resistant influenza B viruses.

133 NAI-resistant substitutions in NA subtypes other than N1

134 We identified not only numerous NAI-resistant substitutions previously reported in other

135 nd B virus infections, so the development of NAI-resistant viruses with superior fitness is a public

136 ss of the risk assessment for the fitness of NAIs-resistant seasonal H1N1 and H3N2, pandemic 2009 H1N

137 d HA, a single vaccine dose induced a strong NAi response that was not significantly boosted by a sec

138 %, whereas the inhibition of NF-kappaB using NAI resulted in a decrease in females from 45 to 20%.

139 complexes with a different concentration of NaI showed that the mutations decreased affinity between

140 seltamivir, an oral neuraminidase inhibitor (NAI), so rapidly determining the effectiveness of NAIs a

141 Without NaI supplementation, 50% of 5- to 6-mo-old CD28(-/-)IFN-

142 mma(-/-) NOD.H-2h4 mice given sodium iodide (NaI)-supplemented water develop a slow onset autoimmune

143 oseltamivir-treated patient were tested for NAI susceptibility in vitro; their replicative fitness w

144 We coinfected NHBE cells with NAI-susceptible and -resistant viruses and used next-gen

145 g-E119A was easily masked by the presence of NAI-susceptible virus.

146 e fitness greater than that of the wild-type NAI-susceptible virus.

147 oxidants produced by a cell-free H2O2-FeSO4-NaI system than were controls.

148 rmance, followed by the large-area dedicated NaI system, and hybrid PET gamma cameras.

149 CZT detector was 76% that of the equivalent NaI system.

150 nominal counting rates were obtained for the NaI systems, and the bismuth germanate (BGO) systems wer

151 As such, conditions under which NAI T cells are activated may determine the magnitude of

152 Furthermore, whether NAI T cells serially differentiate into EFFE and then ME

153 l basis underlying differentiation of naive (NAI) T cells into effector (EFFE) and memory (MEM) cells

154 emonstrated reduced inhibition by all of the NAIs tested in both the backbone of the 2009 H1N1 pandem

155 We found using NaI that the ratio of oxo8dG/10(5 )deoxyguanosine (dG) i

156 Using difluorocarbene, generated from TMSCF3/NaI, these spirocycles were produced in yields up to 97%

157 also showed reduced inhibition by all of the NAIs, though their overall viral fitness was impaired in

158 hibition (HAI) and neuraminidase inhibition (NAI) titer decline in the absence of infection were esti

159 HAI and NAI titers decreased slowly over 18 months; overall, a 2

160 and 9 wk after injection using spectrometric NaI(Tl) and HPGe detectors, and imaging between 5 and 10

161 The camera has a 10 x 10 x 1 cm NaI(Tl) crystal with four photomultipliers.

162 T scanners, is unique in the use of 6 curved NaI(Tl) detectors (2.54 cm thick).

163 Using a NaI(Tl) scintillation detector designed to operate in el

164 ty for acyl transfer from N-acetylimidazole (NAI) to different pyridylcarbinol (PC) regioisomers (2-P

165 high levels of naturally acquired immunity (NAI) to severe malaria; NAI is caused by repeated exposu

166 In cells depleted of Nai+ to inhibit the triggering of sarcoplasmic reticulum

167 NaI-treated and mutant photosystem I complexes were used

168 fitness of H7N9 NA variants that emerged in NAI-treated patients.

169 er research is needed about whether starting NAI treatment >5 days after symptom onset may also conve

170 ed odds of hospital admission compared to no NAI treatment (adjusted odds ratio, 0.24; 95% confidence

171 d a nonsignificant reduction associated with NAI treatment (at any time) versus none (OR, 0.72 [95% C

172 NAI treatment (at any time) versus none was associated w

173 ision tumour', which was only detected after NAI treatment of baseline ER+ disease.

174 NAI treatment of critically ill pH1N1 patients improves

175 gression modeling to determine the effect of NAI treatment on hospitalization.

176 We investigated the impact of outpatient NAI treatment on subsequent hospitalization in patients

177 We adjusted for NAI treatment propensity and preadmission antibiotic use

178 adjustment for preadmission antibiotics and NAI treatment propensity, preadmission NAI treatment was

179 luenza A(H1N1) pandemic, early initiation of NAI treatment reduced the likelihood of severe outcomes

180 spitalization, outpatient or community-based NAI treatment significantly reduced the likelihood of re

181 e median time from symptom onset to starting NAI treatment was 4 days (range, 0-52 days).

182 s and NAI treatment propensity, preadmission NAI treatment was associated with decreased odds of hosp

183 NAI treatment was associated with survival: 107 of 183 u

184 5.8%) received outpatient or community-based NAI treatment, 928 of 2395 (38.8%) with available data h

185 h information available, 1676 (90%) received NAI treatment, and 183 (10%) did not.

186 atients with severe influenza should receive NAI treatment.

187 The impact of neuraminidase inhibitor (NAI) treatment on clinical outcomes of public health imp

188 4 months of neoadjuvant aromatase inhibitor (NAI) treatment.

189 or two water molecules are able to detach an NaI unit from the Na(3)I(2)(+) cluster.

190 fference in the energies required to lose an NaI unit from these two species.

191 ent also confirms that the loss of a neutral NaI unit, instead of an Na(+) ion, occurs during the dis

192 the dissolution processes, loss of a neutral NaI unit, occurs when six or more water molecules have b

193 Conceptually, the NAI value of an allele is a relative measure of its elev

194 To illustrate its utility, we calculate NAI values for the entire coding sequence and across a s

195 Nai;ve animals recovering from ischemia took longer to r

196 unity, invertebrate hosts are believed to be nai;ve at each new encounter with pathogens.

197 te in Drosophila that Clock misexpression in nai;ve brain regions induces circadian gene expression.

198 In quiescent nai;ve lymphocytes, antigen recognition with appropriate

199 Cohabitation of sexually nai;ve male and female prairie voles (Microtus ochrogast

200 Nai;ve myogenic cells migrate from the somites into the

201 residues in framework stabilization, we used nai;ve phage-displayed libraries, combinatorial alanine-

202 Sexually nai;ve prepubertal and adult male hamsters were exposed

203 sented by mature dendritic cells in the DLN, nai;ve T cells can respond to self antigens or tumor ant

204 Rather, the conditions under which nai;ve T cells encounter antigen in the DLN can result i

205 Nai;ve T cells in the draining lymph node (DLN) do not i

206 sectional study, three different age sets of nai;ve TgCRND8 and non-Tg mice were tested: 10-12, 12-14

207 ant preconcentration and alignment of PC and NAI via coordination to framework porphyrin sites (orien

208 and ATP-induced processing were blocked when NaI was substituted for NaCl within the medium; substitu

209 tissue after 2 Gy of gamma-irradiation when NaI was used to isolate DNA.

210 Susceptibility of N9 viruses to NAIs was determined in a fluorescence-based assay.

211 Susceptibility to NA inhibitors (NAIs) was evaluated with a fluorometric assay using the

212 As Nai+ was decreased, the amount of charge measured and it

213 AT), all TGF-beta transgenic (Tg) mice given NaI water for 2-7 mo developed thyroid lesions character

214 ctions of anti-CD25 developed SAT 8 wk after NaI water.

215 i.e., starting 4 wk after administration of NaI water.

216 ccines will perform in regions with existing NAI, we developed a simple malaria model incorporating v

217 the labeling of arylstannanes using [(125)I]NaI, where products were isolated in high specific activ

218 changes conferring reduced susceptibility to NAIs, which are subtype specific.